Dr. John Cush RheumNow
5 years 11 months ago
When diagnosing Febrile, possible autoinflammatory, Stills disorders do you order genetic testing
Dr. John Cush RheumNow
5 years 11 months ago
Rheum Now shares Day 3 highlights from #ACR20.
https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh
MGH Rheumatology MGHrheumatology
5 years 11 months ago
Congratulations to House of DMARDs, our new @ACRheum 2020 Knowledge Bowl Champions!! 🏆 We are so proud!! @kmdsilvaMD @JonathanDauMD @NasrallahMazen #ACR20 https://t.co/iFaMRNB5D3
The Lancet Rheumatology TheLancetRheum
5 years 11 months ago
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20
Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
Michael Ombrello MichaelOmbrello
5 years 11 months ago
These kind of studies must be done, but this result is to nobody’s surprise! #PedsRheum
Let’s keep working together to move the bar towards recognition that #sJIA and #AOSD are a single condition that can affect people of all ages! https://t.co/qzbgeKPlqw
Janet Pope Janetbirdope
5 years 11 months ago
Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/hjwYvCFJPk
Janet Pope Janetbirdope
5 years 11 months ago
Join now. Free to #ACR20 attendees. Women leaders in rheumatology @RheumNow @CRASCRRheum https://t.co/nIqZ8qTINY
Pregnancy in SLE is a high risk situation and active disease can lead to fetal loss, pre-term birth, IUGR and neonatal lupus syndromes. In a study by Dr. Michelle Petri and colleagues, they evaluated whether the LLDAS at the start of pregnancy was predictive of pregnancy outcome.
Belimumab in Lupus Nephritis: Dr. Janet Pope
Dr. Janet Pope reviews abstract #1441 presented at the 2020 ACR annual meeting.
Dr. John Cush RheumNow
5 years 11 months ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
alexa meara lexmeara
5 years 11 months ago
Awesome succinct guidelines!#acrbest #acr20 @RheumNow https://t.co/lzLykOY8G0
Bella Mehta bella_mehta
5 years 11 months ago
VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe
Robert B Chao, MD doctorRBC
5 years 11 months ago
Mavrilimumab (anti GM-CSF receptor α Mab) efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
1⃣Disease flare 19% in tx vs. 46% in PBO at 26wk
2⃣Sustained remission 83% vs. 50% in PBO
3⃣Similar AE in both groups
@RheumNow #ACR20 Abs#L06 https://t.co/LqiNKJffFo
Olga Petryna DrPetryna
5 years 11 months ago
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group
Meral K. El Ramahi, MD MeralElRamahiMD
5 years 11 months ago
#ACR20 @RheumNow https://t.co/ImXVcDIl4V
